Tango Therapeutics (NASDAQ:TNGX) Stock Gets Price Target Reduction from HC Wainwright

Posted by Stanley Muller on Nov 10th, 2026

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) had its target price cut by equities research analysts at HC Wainwright from $68.00 to $67.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright‘s price target indicates a potential upside of 194.64% from the company’s previous close.

Several other equities analysts have also weighed in on the stock. Guggenheim increased their price target on shares of Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tango Therapeutics in a research report on Wednesday, November 4th. Wall Street Zen cut shares of Tango Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. JPMorgan Chase & Co. initiated coverage on shares of Tango Therapeutics in a research note on Wednesday, July 15th. They issued an “overweight” rating and a $46.00 target price on the stock. Finally, William Blair assumed coverage on shares of Tango Therapeutics in a research report on Friday, October 16th. They set an “outperform” rating for the company. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.54.

Read Our Latest Stock Report on Tango Therapeutics

Tango Therapeutics Price Performance

Shares of NASDAQ:TNGX opened at $22.74 on Tuesday. The company has a market capitalization of $3.83 billion, a PE ratio of -26.75 and a beta of 1.26. The business has a fifty day moving average price of $23.32 and a two-hundred day moving average price of $22.53. Tango Therapeutics has a 1 year low of $7.49 and a 1 year high of $34.39.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Sell-side analysts anticipate that Tango Therapeutics will post -1.41 earnings per share for the current year.

Insider Activity

In other Tango Therapeutics news, insider Adam Crystal sold 27,000 shares of the firm’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $24.47, for a total value of $660,690.00. Following the completion of the transaction, the insider owned 115,743 shares in the company, valued at $2,832,231.21. This trade represents a 18.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jessica Newcomb sold 8,200 shares of Tango Therapeutics stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $24.22, for a total value of $198,604.00. Following the transaction, the insider directly owned 59,121 shares of the company’s stock, valued at $1,431,910.62. The trade was a 12.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 47,231 shares of company stock valued at $1,129,029. 6.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tango Therapeutics

Several hedge funds have recently bought and sold shares of the company. TRV GP IV LLC bought a new stake in Tango Therapeutics during the 2nd quarter worth approximately $120,181,383,000. BlackRock Inc. purchased a new position in shares of Tango Therapeutics during the 2nd quarter valued at $388,826,000. Jupiter Topco LLC purchased a new position in shares of Tango Therapeutics during the 2nd quarter valued at $157,989,000. Seven Fleet Capital Management LP grew its position in shares of Tango Therapeutics by 302.2% during the 2nd quarter. Seven Fleet Capital Management LP now owns 3,228,144 shares of the company’s stock valued at $95,661,000 after purchasing an additional 2,425,484 shares in the last quarter. Finally, Jefferies Financial Group Inc. bought a new position in shares of Tango Therapeutics in the second quarter worth $62,849,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

(Get Free Report)

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells.

Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.

Founded in 2017, Tango was established to apply advances in cancer genetics and functional genomics to drug discovery.